Document Detail

Human osteoblast-like cells and osteosarcoma cell lines synthesize macrophage inhibitory protein 1alpha in response to interleukin 1beta and tumour necrosis factor alpha stimulation in vitro.
MedLine Citation:
PMID:  10691855     Owner:  NLM     Status:  MEDLINE    
Recent investigations have demonstrated that macrophage inhibitory protein 1alpha (MIP-1alpha) plays a critical role in haematopoiesis. In part, MIP-1alpha limits the differentiation of early haematopoietic cells, thereby ensuring that sufficient quantities of blood precursors are available to meet haematopoietic demands. MIP-1alpha is produced by cells of the marrow microenvironment (marrow stromal cells) in response to a variety of stimuli, including interleukin 1beta (IL-1beta) and tumour necrosis factor alpha (TNF-alpha). Our recent investigations demonstrated that normal human osteoblast-like cells (HOBs) maintain the early phenotype of haematopoietic precursors, like other members of the bone marrow stroma. Although the precise molecular mechanisms for these observations have not been determined, the production of MIP-1alpha remains one such possibility. In the present study, we investigated whether cells of the osteoblast lineage under basal, IL-1beta and/or TNF-alpha stimulation produce MIP-1alpha. We observed that IL-1beta and TNF-alpha stimulated HOBs and human osteosarcoma cells to rapidly express MIP-1alpha mRNA and to secrete large quantities of the protein. MIP-1alpha mRNA and protein was not, however, detected under basal conditions. Perhaps more importantly, enriched human CD34+ bone marrow cells in co-culture may be capable of stimulating the expression of MIP-1alpha mRNA by HOBs in vitro. These findings suggest that human osteoblast-like cells may produce MIP-1alpha in vivo to support haematopoiesis at sites where osteoblasts and haematopoietic cells are closely associated.
R S Taichman; M J Reilly; L S Matthews
Related Documents :
22436355 - Neuroprotective effects of chronic exposure of sh-sy5y to low lithium concentration inv...
16127705 - Ultrastructural evidence for secretion from the epithelium of ampulla ductus deferentis...
17409405 - Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a ...
2420365 - Arachidonic acid metabolism by isolated epidermal basal and differentiated keratinocyte...
19366455 - Bmp-2 signaling in ovarian cancer and its association with poor prognosis.
7900965 - Toxicity evaluation of the mycotoxins, citrinin and ochratoxin a, using several animal ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  British journal of haematology     Volume:  108     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2000 Feb 
Date Detail:
Created Date:  2000-04-13     Completed Date:  2000-04-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  275-83     Citation Subset:  IM    
Department of Periodontics,, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Neoplasms / metabolism*
Chemokine CCL3
Chemokine CCL4
Enzyme-Linked Immunosorbent Assay
Interleukin-1 / pharmacology*
Macrophage Inflammatory Proteins / biosynthesis*
Osteoblasts / metabolism*
Osteosarcoma / metabolism*
RNA, Messenger / metabolism
Reverse Transcriptase Polymerase Chain Reaction
Stromal Cells / metabolism
Tumor Cells, Cultured
Tumor Necrosis Factor-alpha / pharmacology*
Grant Support
Reg. No./Substance:
0/Chemokine CCL3; 0/Chemokine CCL4; 0/Interleukin-1; 0/Macrophage Inflammatory Proteins; 0/RNA, Messenger; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism.
Next Document:  Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease.